1047630-73-8

Basic information

• Product Name: N-[2-AMINO-2-(3-CHLOROPHENYL)ETHYL]-CARBAMIC ACID 1,1-DIMETHYLETHYL ESTER
• Synonyms: N-[2-AMINO-2-(3-CHLOROPHENYL)ETHYL]-CARBAMIC ACID 1,1-DIMETHYLETHYL ESTER;2-(Boc-amino)-1-(3-chlorophenyl)ethylamine
• CAS NO: 1047630-73-8
• Molecular Formula: C₁₃H₁₉ClN₂O₂
• Molecular Weight: 270.75516
• Mol File: 1047630-73-8.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: N-[2-AMINO-2-(3-CHLOROPHENYL)ETHYL]-CARBAMIC ACID 1,1-DIMETHYLETHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: N-[2-AMINO-2-(3-CHLOROPHENYL)ETHYL]-CARBAMIC ACID 1,1-DIMETHYLETHYL ESTER(1047630-73-8)
• EPA Substance Registry System: N-[2-AMINO-2-(3-CHLOROPHENYL)ETHYL]-CARBAMIC ACID 1,1-DIMETHYLETHYL ESTER(1047630-73-8)

Safety Data

• Hazardous Substances Data: 1047630-73-8(Hazardous Substances Data)

Usage

Uses

Used in Pesticide Applications:
Tolprocarb is used as an insecticide for controlling a wide range of pests in various crops, including vegetables, fruit trees, and ornamental plants. It is effective in managing pests that can cause significant damage to these crops, thereby protecting the yield and quality of the produce.
Used in Agriculture Industry:
In the agriculture industry, tolprocarb is used as a pesticide to protect crops from insect infestations. Its ability to inhibit acetylcholinesterase in insects makes it a valuable tool for controlling pests that can cause substantial damage to crops, ensuring a healthy and productive agricultural output.
It is important to handle and use tolprocarb with caution, as it can be toxic to humans and other non-target organisms if not properly managed. Proper safety measures and guidelines should be followed to minimize the risk of exposure and potential harm.

Upstream product

• 1386398-77-1 [2-(3-Chloro-phenyl)-2-(1,3-di oxo-1,3-dihydro-isoindol-2-yl)-ethyl]-carbamic acid tert-butyl ester 
• 1187983-89-6 [2-(3-chloro-phenyl)-2-hydroxy-ethyl]-carbamic acid tert-butyl ester 
• 97070-75-2 2-(3-chlorophenyl)-2-hydroxyacetonitrile 
• 53360-89-7 2-amino-1-(3-chloro-phenyl)-ethanol 
• 587-04-2 m-Chlorobenzaldehyde 

Downstream Products

• 1400670-64-5 (2-(3-chloro-phenyl)-2-{6-[8-(2-morpholin-4-yl-ethylamino)-imidazo[1,2-a]pyrazin-3-yl]-pyridin-2-ylamino}-ethyl)-carbamic acid tert-butyl ester 
• 1400670-54-3 (2-(3-chloro-phenyl)-2-{4-[8-(4-methyl-piperazin-1-yl)-imidazo[1,2-a]pyrazin-3-yl]-pyrimidin-2-ylamino}-ethyl)-carbamic acid tert-butyl ester 
• 1400670-07-6 1-(3-chlorophenyl)-N₁-{4-[8-(4-methylpiperazin-1-yl)imidazo[1,2-a]pyrazin-3-yl]pyrimidin-2-yl}ethane-1,2-diamine hydrochloride 
• 1386981-27-6 (S)-2-{4-chloro-3-[(2-methoxy-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carbonyl)amino]benzoylamino}-2-(3-chloro-phenyl-ethyl)carbamic acid tert-butyl ester 
• 1386980-14-8 2-methoxy-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carboxylic acid {5-[(S)-2-amino-1-(3-chloro-phenyl)ethylcarbamoyl]-2-chloro-phenyl}amide 
• 1386979-80-1 2-Methoxy-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carboxylic acid {5-[2-amino-1-(3-chloro-phenyl)-ethylcarbamoyl]-2-chloro-phenyl}-amide 
• 1386399-50-3 [4-(3-{2-[2-tert-butoxycarbonylamino-1-(3-chloro-phenyl)-ethylamino]-pyrimidin-4-yl}-1H-pyrazolo[3,4-d]pyrimidin-6-ylamino)-cyclohexyl]-carbamic acid tert-butyl ester 
• 1386398-57-7 N-(3-{2-[2-amino-1-(3-chloro-phenyl)-ethylamino]-pyrimidin-4-yl}-1H-pyrazolo[3,4-d]pyrimidin-6-yl)-cyclohexane-1,4-diamine hydrochloride 
• 1269928-33-7 (S)-tert-butyl (2-amino-2-(3-chlorophenyl)ethyl)carbamate 
• 1269810-89-0 [(R)-2-amino-2-(3-chloro-phenyl)-ethyl]-carbamic acid tert-butyl ester 
• 1387641-32-8 6,7-Dimethoxy-2-oxo-1,2-dihydro-quinoline-3-carboxylic acid [5-[2-amino-1-(3-chloro-phenyl)-ethylcarbamoyl]-2-methyl-phenyl]-amide 
• 1386980-89-7 [2-{4-chloro-3-[(2-methoxy-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carbonyl)-amino]-benzoylamino}-2-(3-chloro-phenyl)-ethyl]-carbamic acid tert-butyl ester 

Relevant articles and documents

BENZOPYRAZOLE COMPOUND USED AS RHO KINASE INHIBITOR

The invention relates to a benzopyrazole compound used as RHO kinase inhibitor, a pharmaceutical composition and uses thereof for preparing an RHO kinase inhibiting drug, and more specifically to said compound of formula (I-1), a pharmaceutically acceptable salt and isomer thereof.

PYRAZOLO PYRIMIDINES

Compounds of formula and pharmaceutically acceptable salts thereof are described, as well as the pharmaceutical compositions containing said compounds and their pharmaceutically acceptable salts, and the use of said compounds and pharmaceutical compositions for the treatment, control or amelioration of proliferative diseases, including cancer, Down syndrome or early onset Alzheimer's disease.

PYRIDO PYRIMIDINES

Compounds of formula and pharmaceutically acceptable salts thereof are described, as well as the pharmaceutical compositions containing said compounds and their pharmaceutically acceptable salts, and the use of said compounds and pharmaceutical compositions for the treatment, control or amelioration of proliferative diseases, including cancer, Down syndrome or early onset Alzheimer's disease.

CARBOXYLIC ACID ARYL AMIDES

Compounds of formula and pharmaceutically acceptable salts thereof are described, as well as the pharmaceutical compositions containing said compounds and their pharmaceutically acceptable salts, and the use of said compounds and pharmaceutical compositions for the treatment, control or amelioration of proliferative diseases, including cancer.

1,6- AND 1,8-NAPHTHYRIDINES

Compounds of formula and pharmaceutically acceptable salts thereof are described, as well as the pharmaceutical compositions containing said compounds and their pharmaceutically acceptable salts, and the use of said compounds and pharmaceutical compositions for the treatment, control or amelioration of proliferative diseases, including cancer, Down syndrome or early onset Alzheimer's disease.

IMIDAZO PYRAZINES

Compounds of formula and pharmaceutically acceptable salts thereof are described, as well as the pharmaceutical compositions containing said compounds and their pharmaceutically acceptable salts, and the use of said compounds and pharmaceutical compositio

PYRAZOLO PYRIMIDINES AS DYRK1A AND DYRK1B INHIBITORS

Compounds of formula and pharmaceutically acceptable salts thereof are described, as well as the pharmaceutical compositions containing said compounds and their pharmaceutically acceptable salts, and the use of said compounds and pharmaceutical compositions for the treatment, control or amelioration of proliferative diseases, including cancer, Down syndrome or early onset Alzheimer's disease.